According to our new research study on "Alzheimer's Drugs Market Forecast to 2031 - Global Analysis - by Drug Class, End User, and Geography," the market is expected to grow from US$8.24 billion in 2024 to US$26.37 billion by 2031; it is estimated to record a CAGR of 13.6% from 2025-2031. Key factors driving the growth of the Alzheimer's drugs market are the aging population & rising Alzheimer's prevalence, and improved diagnostics & early detection. However, the high cost of disease-modifying therapies hinders the market's growth.

The scope of the Alzheimer's drugs market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. Asia Pacific is anticipated to register the fastest CAGR in the Alzheimer's drugs market from 2025 to 2031. The market growth is attributed to the age-related diseases, such as Alzheimer's, becoming more prevalent in the region. This demographic shift raises demand for effective treatments. Secondly, rising awareness of neurodegenerative disorders, supported by government and non-government initiatives, has led to earlier diagnoses and increased patient engagement. Additionally, economic development and improvements in healthcare infrastructure in the region have expanded access to diagnostic services and advanced treatment options. Increased investment in research and development, from domestic pharmaceutical companies and global players entering the market, fosters innovation and clinical trials in APAC and is bolstering the Alzheimer's drugs market growth in the Asia Pacific. These factors, combined with regulatory reforms and faster drug approval pathways, are encouraging new drug launches. Lifestyle changes and rising rates of diabetes and cardiovascular disease-known risk factors for Alzheimer's, also contribute to the growing patient base, thereby fueling sustained market growth across the Asia-Pacific region.

China, India, and Japan are three significant contributors to the market growth in this region. China faces a rapidly rising burden of Alzheimer's disease, driven by one of the fastest-aging populations in the world. As per the WHO Ageing and Health in China article, the country's population aged 60 and older reached ~254 million in 2019, including nearly 176 million people aged 65 or older. By 2040, the number of people over 60 is projected to reach approximately 402 million, making up 28% of the country's total population. According to a study discussed in the Journal of Health, Population, and Nutrition, the number of people with Alzheimer's disease in China is ~6 million, with dementia rates among 65-, 75-, and 85-year-olds being 5%, 11.5%, and 30%, respectively. China conditionally approved sodium oligomannate (GV-971) in 2019 for mild-to-moderate Alzheimer's, making it the only locally approved disease-modifying therapy. Eisai/Biogen's lecanemab (Leqembi) had received approval in China in January 2024 for early Alzheimer's. Other development programs include Remlifanserin (ACP-204), a serotonin 5-HT?A inverse agonist targeting Alzheimer's psychosis, now in early stages, and combination cholinesterase/NMDA-receptor therapies, which represent the fastest growing drug segment in China.

Moreover, the Japanese government had launched a dementia R&D initiative, pledging ~US$140-200 million (